Presentation ACC 2023 A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes] Presenter: Neha J. Pagidipati March 05, 2023
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2021 Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients Caitlin E. Cox May 07, 2021
Presentation ACC 2020 The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes Presenter: Deepal L. Bhatt March 30, 2020
News Conference News ACC 2020 Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes Yael L. Maxwell March 30, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
Presentation ACC 2018 CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes Presenter: Brendan M. Everett March 12, 2018
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
Presentation ACC 2017 Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk Presenter: Marc Sabatine March 17, 2017